Menu
Logo

SATELLITE SYMPOSIUM & INDUSTRY HUB at EADV 2022

7-8-9 SETTEMBRE 2022

MiCo Milano Convention Centre, Milan, Italy
Partecipazione riservata solo ai medici iscritti a EADV 2022.
banner evento

Exploring the world of bullous pemphigoid: unmet needs and new therapies

13:00-14:00 CEST

Faculty

Pascal Joly (France) (Scientific Committee)
Joost Meijer (Netherlands)
Dedee Murrell (Australia) (Scientific Committee)

Bullous pemphigoid (BP) is the most common autoimmune blistering disease of the skin and mucous membranes, and places a huge burden on the patient, with many unmet needs in treatment. During this symposium, our expert faculty will discuss the pathophysiology of BP, current treatment strategies, and their unmet needs in BP, before looking forward and exploring emerging mechanisms of action and potential therapeutic targets to address these unmet needs in BP management.

Learning objectives
After this symposium, participants should be able to:

  • Describe the pathophysiological mechanisms driving bullous pemphigoid disease aetiology and presentation, and define the current treatments for this disease
  • Examine the unmet clinical needs for bullous pemphigoid patients and emerging treatment pathways
  • Evaluate the emerging treatment pathway of FcRn inhibition as a potential new mechanism of action for the treatment of bullous pemphigoid

Programme (all times in CEST)

13:00–13:05 Welcome and introduction
Dedee Murrell

13:05–13:20 The pathogenesis of and current treatments for bullous pemphigoid
Joost Meijer

13:20–13:35 Spotlighting unmet needs and new therapeutic targets in bullous pemphigoid
Pascal Joly

13:35–13:50 The potential of FcRn inhibition in the treatment of bullous pemphigoid
Dedee Murrell

13:50–14:00 Q&A
All faculty

Closing remarks
Pascal Joly

Managing patients with psoriasis and metabolic syndrome

10:30-11:15 CEST

Faculty

Tom Hillary (Belgium)
Giorgio Sesti (Italy)

Psoriasis patients who present with metabolic syndrome (MetS) face increased disease burden and mortality risk. Managing patients with psoriasis with MetS is also complex. During this session, our expert faculty speakers will discuss current clinical challenges and treatment considerations and options for patients with psoriasis with MetS and offer practical tips to dermatologists on how to screen and manage MetS.

Learning objectives
After this symposium, participants should be able to:

  • Integrate patient and disease characteristics, including clinical features, comorbidities, and quality of life, into disease management
  • Describe the clinical spectrum of metabolic syndrome and the impact on the disease burden of psoriasis
  • Explain the role of pro-inflammatory cytokines contributing to the systemic pathophysiology of psoriasis and metabolic syndrome

Programme (all times in CEST)

10:30–10:35 Welcome and introduction
Tom Hillary

10:35–10:45 The link between psoriasis and metabolic syndrome (MetS)
Tom Hillary

10:45–10:55 Managing patients with psoriasis and MetS
Giorgio Sesti

10:55–11:10 The real world: a case study of patients with obesity and psoriasis
Tom Hillary, Giorgio Sesti

11:10–11:15 Q&A and discussion with the audience
Tom Hillary, Giorgio Sesti

Closing remarks
Tom Hillary

      A voyage through the advances in long-term management of psoriasis

      13:00-14:00 CEST

      Faculty

      Kilian Eyerich (Germany) (Scientific Committee)
      Brian Kirby (Ireland) (Scientific Committee)
      Stefano Piaserico (Italy)

      Psoriasis has a major impact on a patient’s quality of life. Psoriatic lesions may persist for long-periods of time, or even recur after successful treatment due to the involvement of tissue-resident memory T (TRM) cells. Early intervention may hold potential for improving long-term outcomes of psoriasis and changing the disease course. During this symposium, join Prof. Kilian Eyerich, Prof. Brian Kirby, and Prof. Stefano Piaserico as they explore disease memory and its relation to the pathophysiology of psoriasis, guide us through the potential for early intervention in the management of psoriasis, and how we can achieve improved outcomes in the long-term for patients.

      Learning objectives
      After this event, participants should be able to:

      • Describe the benefit of early diagnosis and treatment initiation of psoriasis management based on the latest guidelines and clinical evidence
      • Evaluate different therapies for psoriasis based on real-world evidence and clinical trials regarding long-term safety, efficacy, and patient-reported outcomes
      • Integrate current guidelines, clinical evidence, and patient characteristics to inform decisions on therapy selection and switching for patients with psoriasis

      Programme (all times in CEST)

      13:00–13:05 Welcome and introduction
      Kilian Eyerich

      13:05–13:15 Pathophysiology and disease memory in psoriasis
      Brian Kirby

      13:15–13:25 A guide to the role of early intervention in psoriasis management
      Kilian Eyerich

      13:25–13:35 Achieving long-term management of psoriasis
      Stefano Piaserico

      13:35–13:55 Faculty discussion and Q&A
      All faculty
      Moderated by Kilian Eyerich

      13:55–14:00 Closing remarks
      Brian Kirby

        Pursuing best outcomes for patients with psoriasis and PsA

        13:00-14:00 CEST

        Faculty

        Jo Lambert (Belgium) (Scientific Committee)
        Richard Warren (UK) (Scientific Committee)
        Alen Zabotti (Italy)

        In this live satellite symposium, join our expert panel as they explore the latest data on the management of psoriasis and psoriatic arthritis (PsA). Prof. Richard Warren, Dr Alen Zabotti, and Prof. Jo Lambert will guide you through the efficacy of biologics on skin clearance and patient-reported outcomes, the importance of early intervention in PsA, and the recent updates on real-world evidence in the use of biologics for the treatment of psoriasis. You are kindly invited to participate in the discussion on multidisciplinary management of psoriatic disease and its comorbidities.

        Learning objectives
        After this symposium, participants should be able to:

        • Differentiate therapies for psoriasis based on mechanisms of action, indication, efficacy/effectiveness and safety data, and impact on patient-reported outcomes
        • Explain the benefits of early diagnosis of PsA, and screen patients with psoriasis for PsA to facilitate prompt referral and treatment initiation to optimize outcomes
        • Evaluate the benefits of a multidisciplinary team working approach in the management of psoriasis, PsA, and associated comorbidities

        Programme (all times in CEST)

        13:00–13:05 Welcome and introduction
        Jo Lambert

        13:05–13:15 Efficacy of biologics on psoriasis clearance and PROs
        Richard Warren

        13:15–13:25 Joint efficacy in the treatment of early PsA
        Alen Zabotti

        13:25–13:35 Treatment with biologics in the real world
        Jo Lambert

        13:35–13:55 Multidisciplinary management of psoriasis, PsA, and other comorbidities
        All faculty
        Moderated by Richard Warren

        13:55–14:00 Closing remarks
        Richard Warren

          Exploring personalized care in psoriasis

          14:30-15:15 CEST

          Faculty

          Curdin Conrad (Switzerland)
          Elke de Jong (Netherlands)

          Although in recent years the treatment options have expanded, the burden of psoriasis is complex, and many factors must be taken into account for patient management. During this session, our expert faculty will discuss the role of personalized medicine in the management of psoriasis, combining insights from real-world evidence, and the factors which may influence treatment decisions to help address the unmet needs in psoriasis management.

          Learning objectives
          After this event, participants should be able to:

          • Describe the patient- and disease-characteristics, and potential future outlooks, that could influence psoriasis management
          • Integrate insights from real-world and clinical evidence on psoriasis into clinical practice

          Programme (all times in CEST)

          14:30–14:35 Welcome and introduction
          Curdin Conrad

          14:35–14:50 Insights from real-world evidence for psoriasis
          Elke de Jong

          14:50–15:05 Personalized management of psoriasis
          Curdin Conrad

          15:05–15:15 Q&A
          Curdin Conrad, Elke de Jong

          Closing remarks
          Elke de Jong

            Per registrarsi a EADV 2022